AAIPharma provides contract research services to the pharmaceutical, biotech, and medical device industries. Its outsourcing services run the gamut from drug candidate selection and feasibility studies, to bioanalytical testing and clinical trials management. Its early clinical development division helps evaluate potential compounds and design patient studies. The company's clinical development businesses run large clinical trials for customers around the world. Other services include regulatory support and data management. AAIPharma has divested its pharmaceutical development division, which cranked out small batches of drugs to supply clinical trials and develops oral drug delivery technology.

Instrumentation Laboratory Company develops and manufactures diagnostic medical equipment primarily for hospitals and clinical laboratories around the globe. The company provides critical care systems, hemostasis products, and information management services. Its product lines include GEM and Synthesis analyzers for critical care diagnostics, and ACL and HemosIL analyzers and reagents for automated clot-timing testing. Its products are marketed through global affiliates and third-party distributors. Instrumentation Laboratory was established in 1959 and is a division of private Spanish health care company Werfen Group.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Cougar Biotechnology has joined the fight against one beastly predator -- cancer. The development-stage company acquires and develops drug candidates for treating prostate cancer, as well as cancer affecting the blood, bone marrow, and lymph nodes. It has three candidates in early stages of development, and one that has reached the final stages of drug trials. Cougar specializes in moving candidates through development to regulatory approval. As its late-stage compound reached closer to commercial development, Cougar decided the time was right to merge with a larger entity and was acquired by Johnson & Johnson in 2009.

XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn's disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The company's developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

RemoteMDx, Inc., together with its subsidiaries, markets and deploys offender management programs, combining patented global positioning system tracking technologies, intervention-based monitoring capabilities, and case management services in the United States. It markets, monitors, and sells the TrackerPAL device, which is used to monitor convicted offenders that are on probation or parole in the criminal justice system. The TrackerPAL device utilizes global positioning system and cellular technologies in conjunction with a monitoring center. The company also sells home security and personal emergency response systems. RemoteMDx, Inc. has strategic relationships with Puracom, Inc.; Inovar, Inc.; and euromicron AG. The company is headquartered in Sandy, Utah.

Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company's development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich's ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally.

Cambridge Laboratories Limited company was founded in 1987 and is now owned by its board of directors. Cambridge Laboratories develops and distributes pharmaceuticals to treat the central nervous system, cancer, vitamin deficiency, and other niches. Its product line includes ImmuCyst (for treatment of superficial bladder cancer), Nabilone (chemotherapy-related nausea and vomiting), and Gelclair (oral ulcers and inflammation). Cambridge Labs has distribution alliances to market its products in over 40 countries.

Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii. Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. It offers BioAstin natural astaxanthin, a dietary antioxidant for use as a human nutraceutical and functional food ingredient to support and maintain the body's natural inflammatory response, as well as to enhance skin, muscle, and joint health. The company also provides Spirulina Pacifica, a nutrient-rich dietary supplement used for extra energy, as well as used as a strengthened immune system and source of antioxidant carotenoids. It sells its products to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and to distributors, retailers, and direct consumers in the form of packaged consumer products. The company sells its products through online, as well as through resellers.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.